Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis.
van Marion
Adriana M W
AM
Auwerda
Johannes J A
JJ
Minnema
Monique C
MC
van Oosterom
Rolinda
R
Adelmeijer
Jelle
J
de Groot
Philip G
PG
Leebeek
Frank W G
FW
Sonneveld
Pieter
P
Lokhorst
Henk M
HM
Lisman
Ton
T
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001780:Blood Coagulation Tests; D004359:Drug Therapy, Combination; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D012307:Risk Factors; D013792:Thalidomide / Q000008:administration & dosage; D013923:Thromboembolism / Q000209:etiology*; D020246:Venous Thrombosis / Q000209:etiology*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D013792:Thalidomide